Brief Summary
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator’s choice of therapy in participants with Metastatic Castration-resistant Prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
Intervention / Treatment
- Drug: BMS-986365
- Drug: Enzalutamide
- Drug: Abiraterone
- Drug: Docetaxel
- Drug: Predinsone/Prednisolone
Inclusion Criteria
- Participants must have histologic or cytologic confirmation of adenocarcinomacancer arising from mucus-producing glands in organs of the prostate without small cell or neuro-endocrine features.
- Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scana type of medical imaging that uses a radioactive tracer to detect bone conditions or abnormalities and/or soft tissuetissue/the material that joins, holds up or surrounds inside body parts such as fat, muscle, ligaments and lining around joints lesions on computed tomography/magnetic resonance imagingtests that create detailed images of areas inside the body (CT/MRI).
- Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory – Short Form (BPI-SF) that must be < 4.
- Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).